EWA
ELVN icon

EverSource Wealth Advisors’s Enliven Therapeutics ELVN Stock Holding History

EverSource Wealth Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153 Sell
3
-1
-25% -$42 ﹤0.01% 4274
2026
Q1 		$156 Buy
+4
New +$111 ﹤0.01% 4226
2025
Q4 		– Sell
-84
Closed -$1.72K – 4311
2025
Q3 		$1.72K Buy
84
+21
+33% +$423 ﹤0.01% 3566
2025
Q2 		$1.26K Buy
63
+50
+385% +$947 ﹤0.01% 3670
2025
Q1 		$256 Buy
13
+11
+550% +$237 ﹤0.01% 3643
2024
Q4 		$45 Buy
+2
New +$52 ﹤0.01% 3650

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

EverSource Wealth Advisors's ELVN Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Enliven Therapeutics (ELVN) stake by 25% in Q2 2026, selling an estimated $42 and leaving 3 shares worth $153. The position accounts for ﹤0.01% of the portfolio, ranked #4274.

EverSource Wealth Advisors first reported a position in ELVN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.72K in Q3 2025. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • EverSource Wealth Advisors held 3 shares of Enliven Therapeutics worth $153 as of Q2 2026.
  • EverSource Wealth Advisors sold 1 Enliven Therapeutics share in Q2 2026, an estimated $42.
  • Enliven Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4274 holding.
  • EverSource Wealth Advisors first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Enliven Therapeutics position peaked at $1.72K in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.